证券研究报告：金融工程报告 研究所 分析师:肖承志 SAC 登记编号:S1340524090001 Email:xiaochengzhi@cnpsec.com 研究助理:金晓杰 SAC 登记编号:S1340124100010 Email:jinxiaojie@cnpsec.com 近期研究报告 《Claude 4 系列发布，谷歌上线编程 智能体 Jules——AI 动态汇总 20250526》 - 2025.05.27 《谷歌发布智能体白皮书，Manus 全面 开放注册——AI 动态汇总 20250519》 - 2025.05.20 《证监会修改《重组办法》，深化并购 重组改革——微盘股指数周报 20250518》 - 2025.05.19 《通义千问发布 Qwen-3 模型， DeepSeek 发布数理证明大模型——AI 动态汇总 20250505》 - 2025.05.06 《基金 Q1 加仓有色汽车传媒，减仓电 新食饮通信——公募基金 2025Q1 季报 点评》 - 2025.04.30 《泛消费打开连板与涨幅高度，ETF 资 金平铺机器人、人工智能与芯片—— 行业轮动周报 20250427》 - 20 ...

Report Summary 1. Report Industry Investment Rating The provided content does not mention the report industry investment rating. 2. Core Viewpoints of the Report - High - frequency economic data focuses on four aspects: production heat improved overall with some开工率 rising and others falling; real estate improved marginally; prices continued to decline; shipping indices rose significantly. - Short - term attention should be paid to the implementation of new stable - growth stimulus policies, the recovery of the real estate market, and changes in US tariff policies [2][34]. 3. Summaries According to Relevant Catalogs Production - Steel: On the week of May 30, the coke oven capacity utilization rate decreased by 0.1 pct, the blast furnace开工率 increased by 0.18 pct, and the rebar production decreased by 5.97 tons [3][11]. - Petroleum asphalt: The开工率 decreased by 3.1 pct and declined for two consecutive weeks [3][11]. - Chemicals: The PX开工率 increased by 5.33 pct, and the PTA开工率 decreased by 0.58 pct [3][11]. - Automobile tires: The all - steel tire开工率 decreased by 0.16 pct, and the semi - steel tire开工率 increased by 0.03 pct [3][12]. Demand - Real estate: On the week of May 25, the commercial housing transaction area increased, the inventory - to - sales ratio decreased, the land transaction area increased, and the residential land transaction premium rate rose [4][15]. - Movie box office: It increased by 0.35 billion yuan on the week of May 25 [4][15]. - Automobiles: On the week of May 25, the daily average retail sales of manufacturers increased by 9,648 vehicles, and the daily average wholesale sales increased by 19,637 vehicles [4][18]. - Shipping indices: On the week of May 30, SCFI rose by 30.68%, CCFI rose by 0.92%, and BDI rose by 5.82% [4][22]. Prices - Energy: On May 30, Brent crude oil prices fell by 1.36% to $63.9 per barrel, and coking coal futures prices fell by 9.07% to 741.5 yuan per ton [5][24]. - Metals: On May 30, LME copper, aluminum, and zinc futures prices changed by - 1.22%, - 0.71%, and - 3.06% respectively, and domestic rebar futures prices fell by 3.01% [5][25]. - Agricultural products: The overall price stabilized, with the wholesale price index of agricultural products rising by 0.04%. Pork, eggs, vegetables, and fruits prices changed by - 1.38%, - 1.64%, + 1.41%, and - 0.38% respectively compared with the previous week [5][27]. Logistics - Subway passenger volume: On May 30, the seven - day moving average of Beijing subway passenger volume decreased by 20,800 person - times, while that of Shanghai increased by 128,600 person - times [6][30]. - Flight volume: On May 28, domestic (excluding Hong Kong, Macao, and Taiwan), domestic (Hong Kong, Macao, and Taiwan), and international flight volumes decreased [6][31]. - Urban traffic: On May 30, the seven - day moving average of the peak congestion index in first - tier cities decreased [6][31].

证券研究报告：金融工程报告 发布时间：2025-06-03 研究所 《ETF 大幅流出红利，成长 GRU 行业因 子得分提升较大——行业轮动周报 20250518》 – 2025.05.19 《各大宽基指数成功补缺，融资资金大 幅净流出银行，GRU 模型偏防守——行 业轮动周报 20250511》 - 2025.05.12 《上证指数振幅持续缩小，目标仍为补 缺，机器人 ETF 持续净流入——行业轮 动周报 20250504》 – 20250506 《基金 Q1 加仓有色汽车传媒，减仓电 新食饮通信——公募基金 2025Q1 季报 点评》 - 2025.04.30 《泛消费打开连板与涨幅高度，ETF 资 金平铺机器人、人工智能与芯片——行 业轮动周报 20250427》 – 2025.04.28 《国家队交易特征显著，短期指数仍交 易补缺预期，TMT 类题材仍需等待—— 行业轮动周报 20250427》- 2025.04.21 《融资盘被动爆仓导致大幅净流出， GRU 模型仍未配置成长——行业轮动周 报 20250413》 – 2025.04.14 金工周报 综合金融受益于稳定币表现突出，ETF 资金逢高净 ...

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform" [1] Core Insights - The domestic innovative drug sector is entering a harvest phase with multiple new drug approvals, enhancing the focus on innovative drugs. As of the end of May 2025, a total of 53 new drugs were approved in China, including 30 domestic and 23 imported drugs, covering various treatment areas such as oncology and rare diseases. The upcoming national medical insurance negotiations are expected to accelerate the market entry of successfully approved innovative drugs [4][12][20]. Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 7699.75, with a weekly high of 8490.25 and a low of 6070.89 [1]. Recent Performance - The pharmaceutical and biotechnology sector increased by 2.21% this week, outperforming the CSI 300 index by 3.3 percentage points. Since May 2025, the sector has risen by 7.25%, again surpassing the CSI 300 index by 5.53 percentage points [16][19]. Subsector Performance - The biopharmaceutical sector saw the highest increase of 4.65%, followed by chemical preparations at 4.27%, and medical research outsourcing at 4%. The offline pharmacy sector experienced the largest decline at 2.69% [5][18]. Recommended and Benefiting Stocks - Recommended stocks include: Yingke Medical, Maipu Medical, Yihe Jiaye, Weidian Biology, Gongdong Medical, and others. Benefiting stocks include: Shanhaishan, Yirui Technology, and others [6][25][36]. Key Events and Trends - The approval of innovative drugs is expected to reshape valuations in the domestic innovative drug sector, which is anticipated to be a key investment theme throughout the year. The upcoming national medical insurance negotiations are crucial for the successful market entry of newly approved drugs [4][12][20]. Market Dynamics - The medical device sector is projected to benefit from policies promoting equipment upgrades, with a significant increase in procurement expected in the second quarter of 2025. The sector's current price-to-earnings ratio indicates potential for valuation growth [21][27]. Future Outlook - The report emphasizes the importance of monitoring procurement progress and the potential for a recovery in the medical device sector's performance in the coming quarters [21][23]. Conclusion - The pharmaceutical and biotechnology industry is positioned for growth, driven by innovative drug approvals and supportive policy changes, making it an attractive investment opportunity [4][12][20].

Group 1: Economic Indicators - The manufacturing PMI for May is 49.5%, up 0.5 percentage points from the previous month, indicating a recovery in market confidence post the China-US Geneva trade talks[13] - The new orders index for manufacturing PMI is 49.8%, an increase of 0.6 percentage points, but still below the expansion threshold[16] - The production index for manufacturing PMI is 50.7%, reflecting a 0.9 percentage point increase, indicating a return to the expansion zone[19] Group 2: Supply and Demand Dynamics - There is a widening supply-demand gap, with the difference between new orders and production PMI at -0.9%, indicating increasing pressure on PPI, which is estimated to decline by 3.4% year-on-year in May[20][22] - Effective demand remains insufficient, constraining economic recovery, with short-term production, investment, and consumption expected to contract[31] - The non-manufacturing business activity index is at 50.3%, slightly down by 0.1 percentage points, but still indicates expansion, supported by the construction and service sectors[25] Group 3: Policy and Market Outlook - The report suggests a cautious market strategy driven by orders, with corporate profitability likely under pressure due to insufficient effective demand and external uncertainties[31] - Investment opportunities are highlighted in high-dividend stocks and industry leaders benefiting from policy incentives, particularly in cross-border tourism and consumption[33] - The upcoming July meeting of the Central Political Bureau is noted as a critical observation point for potential policy adjustments in response to external pressures[33]

证券研究报告：固定收益报告 研究所 分析师:梁伟超 SAC 登记编号:S1340523070001 Email:liangweichao@cnpsec.com 近期研究报告 《2.2%以上，城投开抢？——信用周报 20240526》 - 2025.05.26 固收周报 存单提价风险怎么看？ ——流动性周报 20250602 ⚫ 同业存单继续提价的风险不高 总结而言，上述原因可能导致大行负债压力的前置，但这些矛盾 在 6 月份继续激化的概率不高，同业存单继续提价的空间已经有限。 负债主动前置，也意味的风险的提前暴露，反而减轻了后期的压力。 6 月份的同业存单到期续作压力还在，在大行提前募集 1Y 之后，3M 或是供需两端的共识期限，偏长期限 NCD 供给压力主要看股份行的发 行诉求。大行的存款相对竞争压力小于以往存款降息之后，所谓存款 "脱媒"加大负债压力的同时，也会增加非银产品户对 NCD 和存款的 配置力量，目前影响仅停留在预期层面。信贷投放和长债配置带来的 负债压力，是边际性变化，而非趋势性变化，6 月份政府债券的发行 压力也将减弱。故依然坚持我们对同业存单定价区间的看法，即 1.6% 或是未来资金下行后 ...

证券研究报告：宏观报告 发布时间：2025-06-03 研究所 分析师:李起 SAC 登记编号:S1340524110001 Email:liqi2@cnpsec.com 研究助理:高晓洁 SAC 登记编号:S1340124020001 Email:gaoxiaojie@cnpsec.com 近期研究报告 《费用下行支撑盈利改善，关税分担恐 倒压上游价格》 - 2025.05.28 宏观观点 海外宏观周报：资产价格切换或带来投资机会 ⚫ 核心观点 近期市场最吸引投资者关注就是美股在"解放日"后的大幅反弹 和长端美债收益率的上行。前者的主要原因是关税降级、宏观经济韧 性和一季度美股盈利超预期，而后者的主要原因是降息预期的偏鹰调 整和美债供给导致的期限溢价上升。但近期我们观察到这两类资产背 后的逻辑在发生变化。首先是关税的负向冲击很有可能再起，上一轮 "贸易战"中美博弈、拉扯了 2 年之久才达成最终协议，并且近期的 初请失业金人数、资本品订单等指标均指示了私人部门"抢跑"退去 后宏观经济走弱的风险。其次，当前的降息预期偏悲观，从海外投资 者的观点看，大多数认为今年降息的概率较低，同时减税法案在众议 院通过也让市场 ...

Group 1: Legal and Trade Policy Implications - The U.S. International Trade Court overturned Trump's equal tariff measures, stating they exceeded the authority granted by the International Emergency Economic Powers Act (IEEPA) [1] - The ruling questions the legality of tariffs including a 10% base tariff and equal tariffs, potentially leading to their cancellation, but does not affect tariffs based on Section 232 and Section 301 [2] - The court mandated that the administration cease the collection of related tariffs within 10 days, but did not require the refund of already collected tariffs [2] Group 2: Future Tariff Strategies - The ruling increases uncertainty in tariff policies, but the Trump administration may still impose tariffs using alternative legal frameworks such as Section 122, which allows temporary tariffs up to 15% for a maximum of 150 days [3] - Section 232 allows tariffs if imports threaten national security, but requires a cumbersome investigation process by the Department of Commerce [3] - Section 301 has not seen new tariffs this year, likely due to existing tariffs still in effect and limited room for additional tariffs under the Biden administration [3] Group 3: Market and Negotiation Impact - The court's decision limits the Trump administration's ability to impose tariffs, weakening its position in trade negotiations [4] - A potential strategy for the Trump administration could involve short-term tariffs under Section 122 to gain time for further investigations and legislation regarding specific industry tariffs [4] - Risks include uncertainty in higher court rulings and the fluctuating nature of trade negotiations [4]

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [1]. Core Insights - The company has demonstrated rapid growth in its performance, with 2024 revenue reaching 8.813 billion yuan, a year-on-year increase of 22.99%, and a net profit attributable to shareholders of 2.011 billion yuan, up 24.77% [4][10]. - The company operates three main business segments that have all shown significant growth, with revenue from molds, large component machinery, CNC machine tools, and others increasing by 22.73%, 20.31%, 29.30%, and 44.78% respectively [5]. - The company is expanding its global production capacity, with new factories in Thailand and Mexico enhancing its service capabilities [6]. Company Overview - Latest closing price: 61.34 yuan - Total shares: 800 million, circulating shares: 794 million - Total market capitalization: 49.1 billion yuan, circulating market capitalization: 48.7 billion yuan - 52-week high/low: 63.42/34.51 yuan - Debt-to-asset ratio: 15.3% - Price-to-earnings ratio: 24.24 [3]. Financial Performance - In Q1 2025, the company achieved revenue of 2.279 billion yuan, a year-on-year increase of 29.06%, and a net profit of 520 million yuan, up 29.96% [4]. - The company expects revenues for 2025-2027 to be 10.386 billion, 11.767 billion, and 13.076 billion yuan, with corresponding growth rates of 17.85%, 13.29%, and 11.13% [10][12]. - The projected net profits for the same period are 2.356 billion, 2.700 billion, and 3.038 billion yuan, with growth rates of 17.13%, 14.61%, and 12.50% [10][12]. Future Outlook - The company is set to launch new products in the machine tool sector, including horizontal five-axis machining centers, which are expected to attract a growing customer base [7]. - A new high-end casting project is anticipated to boost revenue from large component machinery, with production expected to commence by mid-2025 [6].

Performance Overview - The Wande Micro Stock Index increased by 2.65% over the past week, ranking 2nd among 38 broad-based indices[4] - The index rose by 11.76% in the past month, ranking 1st among 38 broad-based indices[26] - Over the last quarter, the index saw a 17.92% increase, also ranking 1st among 38 broad-based indices[27] - In the past year, the index surged by 75.4%, ranking 2nd among 38 broad-based indices[29] Factor Analysis - The top five internal factors for the micro stocks this week include the leverage factor (0.143), trading volume factor (0.051), and PB inverse factor (0.042) with historical averages of -0.006, -0.08, and 0.034 respectively[5] - The bottom five factors include the unadjusted stock price factor (-0.19) and PE_TTM inverse factor (-0.143), with historical averages of -0.017 and 0.018 respectively[5] Market Sentiment and Predictions - The micro stocks are expected to reach a turning point soon, with a potential buy signal if the weekly drop exceeds 6%[6] - The current market conditions suggest limited room for further declines, indicating a possibility of maintaining high levels without a pullback[6] Calendar Effects - The Wande Micro Stock Index shows positive average returns on Tuesdays and Thursdays, while Mondays and Wednesdays tend to have negative average returns[7] - The index achieved an 84% win rate in February and a 90% win rate in March and May during the 2024-2025 period[7] Risk Factors - Key risks identified include policy risk, public sentiment risk, and liquidity risk[8]